yellow cards
by meredithrobson
on February 13, 2010 at 04:45PM
That yellow cards are available and publicised on line as well . So many people seem to have adverse drug reactions but do not go back to chemist or doctor to obtain the appropriate card.
Why the contribution is important
Feedback on medicines is useful . eg adverse reaction to statins and eg. reaction to preservative in eye drops etc.so that further advice can be given on the written instructions and side effects
Current tags
Posted by
isobel
February 14, 2010 at 02:43PM
Patient entered side-effects could be very misleading. Think of all the reported side effects from a placebo group in research studies!
Posted by
eMC
February 14, 2010 at 10:30PM
A link to the MHRA's YellowCard adverse event reporting system is available from the electronic Medicines Compendium (eMC) at emc.medicines.org.uk. This link was added towards the end of 2009 and has resulted in more submissions to the YellowCard system than from any other non-MHRA source.
Isobel above makes a good point, although the value of the submissions to the YellowCard system from the eMC should be high given that the majority of eMC users are health professionals. We plan to investigate this further with the MHRA.
The eMC, established in 1997 to provide online access to regulated information for medicines approved by the MHRA is readily accessible, requires no user registration or cost to use and currently contains 3755 SPCs and 3209 PILs. The eMC is published by Datapharm, a not-for-profit organisation established by the Association of the British Pharmaceutical Industry (ABPI) in 1977.
Posted by Lawrence Berry (lberry@medicines.org.uk), Datapharm CEO
Isobel above makes a good point, although the value of the submissions to the YellowCard system from the eMC should be high given that the majority of eMC users are health professionals. We plan to investigate this further with the MHRA.
The eMC, established in 1997 to provide online access to regulated information for medicines approved by the MHRA is readily accessible, requires no user registration or cost to use and currently contains 3755 SPCs and 3209 PILs. The eMC is published by Datapharm, a not-for-profit organisation established by the Association of the British Pharmaceutical Industry (ABPI) in 1977.
Posted by Lawrence Berry (lberry@medicines.org.uk), Datapharm CEO
Posted by
klkl
February 23, 2010 at 11:30AM
Whilst the reporting of adverse effects is an important issue. I do not see that it is relevant to the discussion at hand.
This is about whether or not the PILs and SPCs should be made available for all medicines.
A link to http://yellowcard.mhra.gov.uk/ could be included on any system, however, as stated above is not relevant to the discussion.
This is about whether or not the PILs and SPCs should be made available for all medicines.
A link to http://yellowcard.mhra.gov.uk/ could be included on any system, however, as stated above is not relevant to the discussion.
Please log in to add comments
PSUR and other post-markting information is incomplete for most OTC medicines because the general public does not believe that it has a proper mechanism for reporting side-effects.
Alongside a database of information (PILs etc), the means by which perceived side-effects can be reported by the patient needs to be clearly explained, in lay terms and an option to easily report included as a link on the database.
The lack of reporting for OTC medicines, particularly when patients with chronic conditions experience an adverse reaction due to unforeseen interactions,is a major safety gap at the moment.